MDPI and ACS Style
Fedele, P.; Landriscina, M.; Moraca, L.; Cusmai, A.; Gnoni, A.; Licchetta, A.; Guarini, C.; Lanotte, L.; Pappagallo, M.N.; Melaccio, A.;
et al. Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study. Cancers 2024, 16, 3442.
https://doi.org/10.3390/cancers16203442
AMA Style
Fedele P, Landriscina M, Moraca L, Cusmai A, Gnoni A, Licchetta A, Guarini C, Lanotte L, Pappagallo MN, Melaccio A,
et al. Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study. Cancers. 2024; 16(20):3442.
https://doi.org/10.3390/cancers16203442
Chicago/Turabian Style
Fedele, Palma, Matteo Landriscina, Lucia Moraca, Antonio Cusmai, Antonio Gnoni, Antonella Licchetta, Chiara Guarini, Laura Lanotte, Maria Nicla Pappagallo, Assunta Melaccio,
and et al. 2024. "Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study" Cancers 16, no. 20: 3442.
https://doi.org/10.3390/cancers16203442